BRCC shares fell from a previous close of $12.67 to $8.84, a -30.23% decline, during Tuesday's regular session after already sliding -14.6% in after-hours trading. The driver was BRC's Q3 report released after Monday's close: EPS of -$0.28 badly missed the +$0.05 consensus estimate, fueling the after-hours and extended regular-session selloff.

The central target of $43 is the arithmetic mean of four current, verified analyst price targets for Adeia Inc. (ADEA) , ranging from $39 to $50. At the latest closing price of $20.67 (November 2, 2026), reaching $43 would require a very large gain of roughly 108%.

Gartner shares are up roughly 5% over the past 30 days, though the stock pulled back sharply in the session following its third-quarter 2026 report after trading near recent highs. Third-quarter adjusted EPS of $3.59 rose 30% year over year and came in roughly 26% above consensus estimates.

SOPHiA GENETICS shares slid from $7.11 to $6.35, a -10.69% drop, during Tuesday's regular session after opening lower following results. The decline followed a Q3 2026 earnings miss: adjusted EPS of -$0.24 versus the -$0.19 consensus and revenue of $24.3M slightly below the $24.5M estimate.

KNOP dropped -8.92% during regular market hours, closing at $8.88 from a previous close of $9.75, after touching an intraday low of $8.06. No verified news or fundamental catalyst found — the move is likely a large sell order hitting a thinly-traded book, with volume surging to roughly 16x its average.

The central $41 stock price target is the arithmetic mean of six verified analyst price targets reviewed, which ranged from roughly $38 to $44. At a recent closing price of about $35, reaching $41 would require roughly a 17% advance, a substantial but not extreme move.

Waystar Holding (WAY) slid from a $28.14 prior close to $26.65 during regular market hours, a -5.29% decline. The drop extends post-earnings selling: Q3 results beat estimates (adjusted EPS $0.44 vs $0.41; revenue $325.6M), but fiscal 2026 revenue guidance was trimmed below consensus and implied a sequential Q4 revenue decline.

SUPN dropped from $36.28 (prior close) to $29.95 during regular market hours on Nov. 3, a decline of -17.45%. The all-stock merger with Indivior closed Nov. 2, and the combined Supernus, Inc. began trading under SUPN while Supernus was simultaneously removed from the S&P SmallCap 600, triggering forced index-fund selling.

EPAM Systems (EPAM) dropped during regular trading on Tuesday, sliding from a previous close of $143.80 to $136.60, a decline of -5.01%. No verified news or fundamental catalyst found. Two days ahead of its Q3 report (Nov 5) and after rallying roughly +34% since late September, the pullback is consistent with pre-earnings profit-taking and de-risking in a name that routinely swings over 5% in a day.

Stevanato Group (STVN) shares fell roughly 28% over the trailing 30 days, with the bulk of the decline occurring in a single trading session after its third-quarter 2026 report. Third-quarter revenue rose 8% to €326.1 million and adjusted diluted EPS of €0.16 matched consensus, but forward commentary on GLP-1 demand pressured the stock.

Paymentus Holdings (PAY) fell -11.78% during regular trading today, sliding from a $35.05 prior close to $30.92. The drop followed Q3 results released after Monday's close: EPS of $0.25 and revenue of $372.2M both beat estimates, but conservative Q4 guidance—including adjusted EBITDA of $45M–$50M—signaled a sequential profit slowdown and drove the selloff.

Rhythm Pharmaceuticals shares dropped from a prior close of $93.44 to $85.03, a -9.00% decline during regular market trading on November 3. The company reported Q3 2026 results before the open — beating EPS (-$0.61 vs. -$0.71 expected) and revenue ($92.1M vs. $85.4M) — but announced an amended LG Chem bivamelagon license requiring $350M in added payments plus a $750M term loan, and investors focused on rising spending and the financing rather than the beat.

TVTX dropped -7.02%, from a previous close of $49.26 to $45.80, during Tuesday's regular session. The decline follows Q3 2026 earnings reported after Monday's close: a wide EPS miss (GAAP -$0.55 vs. ~$0.02 consensus), driven by a $113.1M in-process R&D charge on the Everest civorebrutinib deal, plus softer Filspari new patient starts.

CVI dropped from a $55.92 prior close to $51.41, a -8.07% decline, during regular market hours after already sliding in premarket trading. The stock fell as CVR Energy unveiled a $4.2 billion deal to acquire two Marathon Petroleum refineries plus marketing operations, funded partly by a dilutive $750 million common-stock offering that overshadowed a strong earnings beat.

BVS shares declined roughly 17.6% over the last 30 days, with most of the move triggered by a third-quarter revenue miss and a cut to full-year guidance. Third-quarter revenue rose 3% to $142 million but came in below consensus estimates near $149.5 million, pressured by softer bone graft substitute (BGS) sales.

Zebra Technologies (ZBRA) slid -9.13% to $328.15 from Monday's $361.13 close during Tuesday's regular session, extending a sharp premarket decline. The drop followed Q3 earnings that beat estimates — adjusted EPS of $4.95 and revenue of $1.61B — as investors focused on a roughly 230-basis-point gross-margin decline to ~45.7% on higher memory costs and an "at least $1 billion" free-cash-flow outlook that fell slightly short of expectations.

MSA Safety (MSA) dropped -6.22% to $174.85 from a prior close of $186.44, during regular market hours Tuesday. The slide followed Q3 results released after Monday's close: adjusted EPS of $2.09 matched estimates and revenue of $536M beat, but operating margin compressed to 16.4% from 20.1% year over year.

ADEA tumbled -13.88% to $17.80 from the prior session's $20.67 close during regular trading, extending an overnight slide that began after Monday's earnings release. The decline followed Q3 results that badly missed estimates and a cut to full-year guidance: adjusted EPS of $0.21 and revenue of $80.2M came in well below consensus, and 2026 revenue guidance was lowered to $375M–$415M.

Ball Corporation (BALL) dropped during regular market hours, falling from $68.07 at the prior close to $63.56, a decline of -6.63%. The selloff followed Ball's Q3 earnings released before the open, which swung to a $94 million GAAP loss ($0.36/share) on a $475 million non-cash U.K. pension buyout charge, triggering profit-taking despite a headline beat.

Leidos Holdings (LDOS) dropped from its previous close of $144.16 to $134.56, a -6.66% decline during regular market hours. The move was driven by Q3 earnings: revenue of $4.63 billion missed estimates, and the company lowered its full-year 2026 revenue guidance to $18.0B–$18.2B, below the analyst consensus of roughly $18.3B.